Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Fimbrial antigen type 2 refers to a class of bacterial surface proteins that form filamentous structures known as fimbriae or pili. These structures are found on the surface of various Gram-negative bacteria—including Salmonella, Actinomyces, and Bordetella pertussis—and play a critical role in mediating adhesion to host cells and colonization during infection. In some species like Actinomyces oris, type 2 fimbria consists primarily of shaft proteins such as FimA and tip adhesins like FimB; their assembly requires specific sortase enzymes (e.g., SrtC2). In Salmonella paratyphi B and related organisms, type 1 and type 2 fimbriae share similar antigens but differ functionally—type 1 mediates adhesion while type 2 may represent mutational variants with reduced adhesive properties but preserved immunogenicity. In the context of Bordetella pertussis, "Fimbrial antigen types 2/3" refer specifically to two serologically distinct forms included as components in acellular pertussis vaccines. These antigens stimulate protective immunity by inducing antibody responses that block bacterial attachment and colonization during infection with B. pertussis—the causative agent of whooping cough. The main clinical application is thus prophylactic vaccination against infectious disease rather than direct therapeutic targeting after infection has occurred. Overall, "Fimbrial antigen type 2" is best understood as a structural bacterial protein complex involved in pathogenesis through adhesion mechanisms—and serves both as an important virulence factor for bacteria and an effective target for vaccine-mediated prevention strategies.
Induction of actively acquired immunity by stimulating an immune response against the bacterial pathogen expressing this antigen when used in vaccines
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Fimbrial antigen type 2.